Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astri Therapeutics Inc (NQ: ATXS )

11.48 +0.15 (+1.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 199,414
Open 11.29
Bid (Size) 11.48 (1)
Ask (Size) 11.51 (1)
Prev. Close 11.33
Today's Range 11.00 - 11.71
52wk Range 2.360 - 16.28
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Earnings Outlook For Astria Therapeutics
 
Via Benzinga

Performance

YTD
-23.67%
-23.67%
1 Month
-9.96%
-9.96%
3 Month
-22.90%
-22.90%
6 Month
+24.65%
+24.65%
1 Year
+76.34%
+76.34%

More News

Read More
Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
From Astria Therapeutics
Via Business Wire
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
Via Benzinga
$10 Million Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Astria Therapeutics, Inc.
Via Business Wire
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
Dow Dips Over 800 Points; S&P 500 Down 2.8%
Via Benzinga
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
RCI Hospitality, AbCellera Biologics And Some Other Big Stocks Moving Higher On Thursday
Via Benzinga
Astria Therapeutics' Potential Hereditary Angioedema Candidate Shows Encouraging Action In Healthy Participants
Via Benzinga
Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development
From Astria Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.